Brown Marie T, LeRoith Derek
a Department of Internal Medicine, Rush University Medical Center, 6326 West Roosevelt Road, Oak Park, IL 60304, USA.
b Division of Endocrinology, Diabetes & Bone Diseases, Mount Sinai School of Medicine, NY, USA.
Expert Rev Endocrinol Metab. 2010 Sep;5(5):741-751. doi: 10.1586/eem.10.45.
As obesity and Type 2 diabetes mellitus reach epidemic proportions worldwide, glycemic control and prevention of complications have become even more critical. We searched studies published between January 2006 and January 2010 to identify and discuss the challenges facing healthcare professionals and patients in reaching glycemic targets. MEDLINE and Derwent Drug File searches were conducted with the following search terms: Type 2 diabetes mellitus, medication adherence, antihyperglycemic agents, glucose control, and clinical inertia. In this article we will outline the commonly used medications and present the advantages and disadvantages of each class of drug. Additionally, we will present the dipeptidyl peptidase-4 inhibitors and their place in the treatment of patients with Type 2 diabetes mellitus.
随着肥胖症和2型糖尿病在全球范围内达到流行程度，血糖控制和并发症预防变得愈发关键。我们检索了2006年1月至2010年1月期间发表的研究，以识别和讨论医疗保健专业人员和患者在实现血糖目标方面面临的挑战。使用以下检索词对医学文献数据库（MEDLINE）和德温特药物档案进行了检索：2型糖尿病、药物依从性、降糖药、血糖控制和临床惰性。在本文中，我们将概述常用药物，并介绍每类药物的优缺点。此外，我们还将介绍二肽基肽酶-4抑制剂及其在2型糖尿病患者治疗中的地位。
